549 related articles for article (PubMed ID: 29953980)
1. Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma.
Tan HY; Wang N; Li S; Hong M; Guo W; Man K; Cheng CS; Chen Z; Feng Y
Cell Physiol Biochem; 2018; 47(5):1819-1834. PubMed ID: 29953980
[TBL] [Abstract][Full Text] [Related]
2. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/β-catenin pathway in hepatocellular carcinoma.
Song J; Xie C; Jiang L; Wu G; Zhu J; Zhang S; Tang M; Song L; Li J
Theranostics; 2018; 8(13):3571-3583. PubMed ID: 30026867
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
[TBL] [Abstract][Full Text] [Related]
5. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
6. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling.
Bai XL; Zhang Q; Ye LY; Liang F; Sun X; Chen Y; Hu QD; Fu QH; Su W; Chen Z; Zhuang ZP; Liang TB
Oncogene; 2015 Jul; 34(31):4089-97. PubMed ID: 25328135
[TBL] [Abstract][Full Text] [Related]
7. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
9. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
10. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin.
Fatima S; Shi X; Lin Z; Chen GQ; Pan XH; Wu JC; Ho JW; Lee NP; Gao H; Zhang G; Lu A; Bian ZX
Mol Oncol; 2016 Feb; 10(2):195-212. PubMed ID: 26474915
[TBL] [Abstract][Full Text] [Related]
11. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
13. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
14. DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway.
Zhang T; Ma Z; Liu L; Sun J; Tang H; Zhang B; Zou Y; Li H
Cell Death Dis; 2018 Jun; 9(6):675. PubMed ID: 29867138
[TBL] [Abstract][Full Text] [Related]
15. UNC119 promotes the growth and migration of hepatocellular carcinoma via Wnt/β/catenin and TGF/β-EMT signaling pathways.
Liu Z; Zhang Y; Xu Z
J BUON; 2018; 23(1):188-192. PubMed ID: 29552782
[TBL] [Abstract][Full Text] [Related]
16. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway.
Chen J; Rajasekaran M; Xia H; Zhang X; Kong SN; Sekar K; Seshachalam VP; Deivasigamani A; Goh BK; Ooi LL; Hong W; Hui KM
Gut; 2016 Sep; 65(9):1522-34. PubMed ID: 26941395
[TBL] [Abstract][Full Text] [Related]
17. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists.
Yuan J; Han B; Hu H; Qian Y; Liu Z; Wei Z; Liang X; Jiang B; Shao C; Gong Y
J Pathol; 2015 Apr; 235(5):784-95. PubMed ID: 25430888
[TBL] [Abstract][Full Text] [Related]
18. Cellular retinol binding protein-1 inhibits cancer stemness via upregulating WIF1 to suppress Wnt/β-catenin pathway in hepatocellular carcinoma.
Liu X; Shan W; Li T; Gao X; Kong F; You H; Kong D; Qiao S; Tang R
BMC Cancer; 2021 Nov; 21(1):1224. PubMed ID: 34775955
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion.
Huang FI; Chen YL; Chang CN; Yuan RH; Jeng YM
Carcinogenesis; 2012 Jun; 33(6):1142-8. PubMed ID: 22436613
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
